Want to see TSE:TMED.X full AI Analyst Report?
EGF Theramed Health (TMED.X) Ratios
EGF Theramed Health Ratios
TSE:TMED.X's free cash flow for Q2 2026 was $-64.44K. For the 2026 fiscal year, TSE:TMED.X's free cash flow was decreased by $-5.00 and operating cash flow was $-64.44K. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.07 | 0.11 | 0.07 | 0.35 |
| Quick Ratio | 0.00 | 0.07 | 0.10 | 0.07 | 0.35 |
| Cash Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 0.29 |
| Solvency Ratio | -0.54 | -0.09 | -0.23 | -0.67 | -0.40 |
| Operating Cash Flow Ratio | 0.01 | -0.05 | -0.33 | -0.40 | -0.33 |
| Short-Term Operating Cash Flow Coverage | 0.02 | -0.09 | 0.00 | -1.18 | -1.02 |
| Net Current Asset Value | $ -5.91M | $ -2.71M | $ -2.48M | $ -2.34M | $ -1.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 67.56 | 6.87 | 6.90 | 6.81 | 0.94 |
| Debt-to-Equity Ratio | -0.33 | -1.10 | -1.17 | -1.19 | 12.26 |
| Debt-to-Capital Ratio | -0.50 | 11.15 | 6.89 | 6.18 | 0.92 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | -4.12 | -0.00 | 0.00 |
| Financial Leverage Ratio | -0.00 | -0.16 | -0.17 | -0.18 | 13.09 |
| Debt Service Coverage Ratio | -2.01 | -0.16 | -15.12 | -1.96 | -1.08 |
| Interest Coverage Ratio | -4.18 | -4.21 | -16.12 | -69.15 | -19.55 |
| Debt to Market Cap | 1.30 | 1.25 | 0.18 | 1.30 | 0.29 |
| Interest Debt Per Share | 0.14 | 0.14 | 0.14 | 0.57 | 1.11 |
| Net Debt to EBITDA | -0.64 | -6.13 | -2.33 | -0.89 | -0.62 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 133.73% | 90.88% | 96.82% | 124.27% | 130.15% |
| EBT Per EBIT | 873.39% | 122.05% | 106.16% | 135.73% | 58.18% |
| Return on Assets (ROA) | -14354.23% | -125.58% | -321.65% | -948.63% | -80.92% |
| Return on Equity (ROE) | 70.87% | 20.09% | 54.51% | 166.18% | -1058.96% |
| Return on Capital Employed (ROCE) | 4.64% | 8.98% | 38.95% | 43.03% | 105.70% |
| Return on Invested Capital (ROIC) | 6.24% | 19.72% | 53.23% | 89.85% | 1434.69% |
| Return on Tangible Assets | -14354.23% | -125.58% | -321.65% | -948.63% | -113.76% |
| Earnings Yield | -276.48% | -22.87% | -12.47% | -262.13% | -36.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.00 | -0.01 | -0.06 | -0.46 | -0.73 |
| Free Cash Flow Per Share | 0.00 | -0.01 | -0.06 | -0.46 | -0.73 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -288006.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -288006.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.02 | -0.09 | -0.43 | -0.82 | -0.70 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | 2.57% | -11.44% | -11.53% | -153.64% | -29.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.36 | -4.37 | -8.02 | -0.38 | -2.77 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.26 | -0.88 | -4.37 | -0.63 | 29.34 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 38.98 | -8.74 | -8.67 | -0.65 | -3.42 |
| Price-to-Operating Cash Flow Ratio | 38.98 | -8.74 | -8.67 | -0.65 | -3.42 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.07 | 0.09 | 0.03 | 0.03 |
| Enterprise Value Multiple | -1.14 | -11.06 | -11.12 | -1.37 | -4.58 |
| Enterprise Value | 2.65M | 2.64M | 6.32M | 1.85M | 3.10M |
| EV to EBITDA | -1.14 | -11.06 | -11.12 | -1.37 | -4.58 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 89.24 | -19.60 | -10.97 | -1.86 | -3.96 |
| EV to Operating Cash Flow | 89.24 | -19.60 | -10.97 | -1.86 | -3.96 |
| Tangible Book Value Per Share | -0.51 | -0.24 | -0.25 | -1.08 | -1.45 |
| Shareholders’ Equity Per Share | -0.39 | -0.12 | -0.11 | -0.47 | 0.09 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.35 | 0.00 | 0.00 | -0.24 | -0.30 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.28 | -0.02 | -0.06 | -0.79 | -0.90 |
| Tax Burden | 1.34 | 0.91 | 0.97 | 1.24 | 1.30 |
| Interest Burden | 1.03 | 1.24 | 1.06 | 1.01 | 1.10 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.01 | 0.50 | 0.90 | 0.73 | 1.05 |
Currency in CAD
